Research Paper Volume 11, Issue 9 pp 2551—2564

MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway

Figure 2. Effect of SIRT1 on regulating the sensitivity of cisplatin to HCC cells. (A) qRT-PCR analysis was performed to detect the expression of SIRT1 in CD133+ and CD133- HepG2 and Huh7 cells at the mRNA level. *P<0.05. (B) Western blot analysis was performed to detect the expression of SIRT1 in CD133+ and CD133- HepG2 and Huh7 cells at the protein level. *P<0.05 vs. HepG2 CD133- cells. #P<0.05 vs. Huh7 CD133- cells. (C) Transfection efficiency of SIRT1 siRNA (50 pmol/mL) and plasmid (2 μg/mL) in CD133+/- HepG2 and Huh7 cells after 24 h transfection. *P<0.05 vs. NCO group. (D) CD133+ and CD133- HepG2 and Huh7 cells were transfected with SIRT1 siRNA (50 pmol/mL) or plasmid (2 μg/mL). 24h later, these cells were treated with cisplatin (10 μM) for another 48 h. MTT assays were performed to measure the cell viability of these cells. *P<0.05 vs. cisplatin + NCO group.